B-intervention	0	11	Trastuzumab
O	12	18	beyond
O	19	30	progression
O	31	33	in
O	34	39	human
O	40	49	epidermal
O	50	56	growth
O	57	63	factor
O	64	72	receptor
O	73	74	2
O	74	75	-
O	75	83	positive
O	84	92	advanced
O	93	99	breast
O	100	106	cancer
O	106	107	:
O	108	109	a
B-location	110	116	german
O	117	123	breast
O	124	129	group
O	130	132	26
O	132	133	/
O	133	139	breast
O	140	153	international
O	154	159	group
O	160	162	03
O	162	163	-
O	163	165	05
O	166	171	study
O	171	172	.

O	173	184	Trastuzumab
O	185	190	shows
O	191	199	clinical
O	200	208	activity
O	209	211	in
O	212	217	human
O	218	227	epidermal
O	228	234	growth
O	235	241	factor
O	242	250	receptor
O	251	252	2
O	253	254	(
O	254	257	HER
O	257	258	-
O	258	259	2
O	259	260	)
O	260	261	-
O	261	269	positive
O	270	275	early
O	276	279	and
O	280	288	advanced
O	289	295	breast
O	296	302	cancer
O	302	303	.

O	304	306	In
O	307	310	the
O	311	317	German
O	318	324	Breast
O	325	330	Group
O	331	333	26
O	333	334	/
O	334	340	Breast
O	341	354	International
O	355	360	Group
O	361	363	03
O	363	364	-
O	364	366	05
O	367	372	trial
O	372	373	,
O	374	376	we
O	377	389	investigated
O	390	392	if
O	393	404	trastuzumab
O	405	414	treatment
O	415	421	should
O	422	424	be
O	425	434	continued
O	435	441	beyond
O	442	453	progression
O	453	454	.

B-eligibility	455	463	Patients
I-eligibility	464	468	with
I-eligibility	469	472	HER
I-eligibility	472	473	-
I-eligibility	473	474	2
I-eligibility	474	475	-
I-eligibility	475	483	positive
I-eligibility	484	490	breast
I-eligibility	491	497	cancer
I-eligibility	498	502	that
I-eligibility	503	513	progresses
I-eligibility	514	520	during
I-eligibility	521	530	treatment
I-eligibility	531	535	with
I-eligibility	536	547	trastuzumab
O	548	552	were
O	553	561	randomly
O	562	570	assigned
O	571	573	to
O	574	581	receive
O	582	594	capecitabine
O	595	596	(
O	596	597	2
O	597	598	,
O	598	601	500
O	602	604	mg
O	604	605	/
O	605	606	m
O	606	607	(
O	607	608	2
O	608	609	)
O	610	614	body
O	614	615	-
O	615	622	surface
O	623	627	area
O	628	630	on
O	631	635	days
O	636	637	1
O	638	645	through
O	646	648	14
O	649	650	[
O	650	651	1
O	651	652	,
O	652	655	250
O	656	658	mg
O	658	659	/
O	659	660	m
O	660	661	(
O	661	662	2
O	662	663	)
O	664	668	semi
O	668	669	-
O	669	674	daily
O	674	675	]
O	675	676	)
O	677	682	alone
O	683	685	or
O	686	690	with
O	691	703	continuation
O	704	706	of
O	707	718	trastuzumab
O	719	720	(
O	720	721	6
O	722	724	mg
O	724	725	/
O	725	727	kg
O	728	732	body
O	733	739	weight
O	739	740	)
O	741	743	in
O	744	745	3
O	745	746	-
O	746	750	week
O	751	757	cycles
O	757	758	.

O	759	762	The
O	763	770	primary
O	771	774	end
O	775	780	point
O	781	784	was
B-outcome-Measure	785	789	time
I-outcome-Measure	790	792	to
I-outcome-Measure	793	804	progression
O	804	805	.

O	806	808	We
O	809	817	randomly
O	818	826	assigned
B-control-participants	827	829	78
O	830	838	patients
O	839	841	to
B-control	842	854	capecitabine
O	855	858	and
B-intervention-participants	859	861	78
O	862	870	patients
O	871	873	to
B-intervention	874	886	capecitabine
I-intervention	887	891	plus
I-intervention	892	903	trastuzumab
O	903	904	.

B-cv-bin-abs	905	910	Sixty
I-cv-bin-abs	910	911	-
I-cv-bin-abs	911	915	five
B-outcome	916	922	events
O	923	926	and
B-cv-bin-abs	927	929	38
B-outcome	930	936	deaths
O	937	939	in
O	940	943	the
O	944	956	capecitabine
O	957	962	group
O	963	966	and
B-iv-bin-abs	967	969	62
O	970	976	events
O	977	980	and
B-iv-bin-abs	981	983	33
B-outcome	984	990	deaths
O	991	993	in
O	994	997	the
O	998	1010	capecitabine
O	1010	1011	-
O	1011	1015	plus
O	1015	1016	-
O	1016	1027	trastuzumab
O	1028	1033	group
O	1034	1042	occurred
O	1043	1049	during
O	1050	1052	15
O	1052	1053	.
O	1053	1054	6
O	1055	1061	months
O	1062	1064	of
O	1065	1071	follow
O	1071	1072	-
O	1072	1074	up
O	1074	1075	.

B-outcome	1076	1082	Median
I-outcome	1083	1088	times
I-outcome	1089	1091	to
I-outcome	1092	1103	progression
O	1104	1108	were
B-iv-cont-median	1109	1110	5
I-iv-cont-median	1110	1111	.
I-iv-cont-median	1111	1112	6
I-iv-cont-median	1113	1119	months
O	1120	1122	in
O	1123	1126	the
O	1127	1139	capecitabine
O	1140	1145	group
O	1146	1149	and
B-cv-cont-median	1150	1151	8
I-cv-cont-median	1151	1152	.
I-cv-cont-median	1152	1153	2
I-cv-cont-median	1154	1160	months
O	1161	1163	in
O	1164	1167	the
O	1168	1180	capecitabine
O	1180	1181	-
O	1181	1185	plus
O	1185	1186	-
O	1186	1197	trastuzumab
O	1198	1203	group
O	1204	1208	with
O	1209	1211	an
O	1212	1222	unadjusted
O	1223	1229	hazard
O	1230	1235	ratio
O	1236	1238	of
O	1239	1240	0
O	1240	1241	.
O	1241	1243	69
O	1244	1245	(
O	1245	1247	95
O	1247	1248	%
O	1249	1251	CI
O	1251	1252	,
O	1253	1254	0
O	1254	1255	.
O	1255	1257	48
O	1258	1260	to
O	1261	1262	0
O	1262	1263	.
O	1263	1265	97
O	1265	1266	;
O	1267	1270	two
O	1270	1271	-
O	1271	1276	sided
O	1277	1280	log
O	1280	1281	-
O	1281	1285	rank
O	1286	1287	P
O	1288	1289	=
O	1290	1291	.
O	1291	1295	0338
O	1295	1296	)
O	1296	1297	.

B-outcome	1298	1305	Overall
I-outcome	1306	1314	survival
I-outcome	1315	1320	rates
O	1321	1325	were
B-iv-cont-median	1326	1328	20
I-iv-cont-median	1328	1329	.
I-iv-cont-median	1329	1330	4
I-iv-cont-median	1331	1337	months
O	1338	1339	(
O	1339	1341	95
O	1341	1342	%
O	1343	1345	CI
O	1345	1346	,
O	1347	1349	17
O	1349	1350	.
O	1350	1351	8
O	1352	1354	to
O	1355	1357	24
O	1357	1358	.
O	1358	1359	7
O	1359	1360	)
O	1361	1363	in
O	1364	1367	the
O	1368	1380	capecitabine
O	1381	1386	group
O	1387	1390	and
B-cv-cont-median	1391	1393	25
I-cv-cont-median	1393	1394	.
I-cv-cont-median	1394	1395	5
I-cv-cont-median	1396	1402	months
O	1403	1404	(
O	1404	1406	95
O	1406	1407	%
O	1408	1410	CI
O	1410	1411	,
O	1412	1414	19
O	1414	1415	.
O	1415	1416	0
O	1417	1419	to
O	1420	1422	30
O	1422	1423	.
O	1423	1424	7
O	1424	1425	)
O	1426	1428	in
O	1429	1432	the
O	1433	1445	capecitabine
O	1445	1446	-
O	1446	1450	plus
O	1450	1451	-
O	1451	1462	trastuzumab
O	1463	1468	group
O	1469	1470	(
O	1470	1471	P
O	1472	1473	=
O	1474	1475	.
O	1475	1478	257
O	1478	1479	)
O	1479	1480	.

B-outcome	1481	1488	Overall
I-outcome	1489	1497	response
I-outcome	1498	1503	rates
O	1504	1508	were
B-cv-bin-percent	1509	1511	27
I-cv-bin-percent	1511	1512	.
I-cv-bin-percent	1512	1513	0
I-cv-bin-percent	1513	1514	%
O	1515	1519	with
O	1520	1532	capecitabine
O	1533	1536	and
B-iv-bin-percent	1537	1539	48
I-iv-bin-percent	1539	1540	.
I-iv-bin-percent	1540	1541	1
I-iv-bin-percent	1541	1542	%
O	1543	1547	with
O	1548	1560	capecitabine
O	1561	1565	plus
O	1566	1577	trastuzumab
O	1578	1579	(
O	1579	1583	odds
O	1584	1589	ratio
O	1589	1590	,
O	1591	1592	2
O	1592	1593	.
O	1593	1595	50
O	1595	1596	;
O	1597	1598	P
O	1599	1600	=
O	1601	1602	.
O	1602	1606	0115
O	1606	1607	)
O	1607	1608	.

O	1609	1621	Continuation
O	1622	1624	of
O	1625	1636	trastuzumab
O	1637	1643	beyond
O	1644	1655	progression
O	1656	1659	was
O	1660	1663	not
O	1664	1674	associated
O	1675	1679	with
O	1680	1689	increased
B-outcome	1690	1698	toxicity
O	1698	1699	.

O	1700	1712	Continuation
O	1713	1715	of
O	1716	1727	trastuzumab
O	1728	1732	plus
O	1733	1745	capecitabine
O	1746	1752	showed
O	1753	1754	a
O	1755	1766	significant
O	1767	1778	improvement
O	1779	1781	in
O	1782	1789	overall
O	1790	1798	response
O	1799	1802	and
O	1803	1807	time
O	1808	1810	to
O	1811	1822	progression
O	1823	1831	compared
O	1832	1836	with
O	1837	1849	capecitabine
O	1850	1855	alone
O	1856	1858	in
O	1859	1864	women
O	1865	1869	with
O	1870	1873	HER
O	1873	1874	-
O	1874	1875	2
O	1875	1876	-
O	1876	1884	positive
O	1885	1891	breast
O	1892	1898	cancer
O	1899	1902	who
O	1903	1914	experienced
O	1915	1926	progression
O	1927	1933	during
O	1934	1945	trastuzumab
O	1946	1955	treatment
O	1955	1956	.
